ACADIA PHARMACEUTICALS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.2 USD | +2.32% |
|
-10.97% | -51.29% |
| 10/05 | UBS Cuts Price Target on ACADIA Pharmaceuticals to $25 From $27, Keeps Buy Rating | MT |
| 10/05 | Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $17 From $19, Maintains Perform Rating | MT |
Presenter SpeechKathie Bishop (Executives)Good day, ladies and gentlemen, and welcome to Acadi...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
14.86
USD
Average target price
27.16
USD
Spread / Average Target
+82.76%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -51.29% | 2.46B | |
| +28.81% | 49.18B | |
| +1.20% | 42.11B | |
| +50.47% | 40.37B | |
| -5.26% | 28.85B | |
| +13.95% | 26.09B | |
| -22.06% | 18.71B | |
| +7.89% | 13.26B | |
| +32.46% | 12.32B | |
| -0.11% | 11.99B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- Transcript : ACADIA Pharmaceuticals Inc., Q3 2023 Earnings Call, Nov 02, 2023
